Area of research
Infectious Diseases · Epidemiology
Research interest
Research interests include Antifungal resistance and susceptibility, Fungal Infections and Studies, Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, and Pneumocystis jirovecii pneumonia detection and treatment.
Mucorales PCR Testing in Respiratory and Biopsy Samples From Immunocompromised Patients With Invasive Pulmonary Aspergillosis and Other Mold Infections: Results From a Multicenter ECMM Study.
Diagnostic accuracy of Mucorales PCR testing in bronchoalveolar lavage fluid samples: a retrospective analysis of a prospectively collected cohort.
Treatment Monitoring and Outcome Prediction in Invasive Aspergillosis using Immunologic Markers.
Clinical Characteristics, Management and Outcomes of Nonintensive Care Unit Candidemia: Subanalysis of the ECMM <i>Candida</i> III Multinational European Observational Cohort Study.
Posaconazole for Prevention of COVID-19-Associated Pulmonary Aspergillosis in Mechanically Ventilated Patients: A European Multicentre Case-Control Study (POSACOVID).
Risk factors for persistent candidemia and prognostic implications: Results from the ECMM Candida III study
Which trial do we need? Shorter antifungal treatment for candidemia - challenging the 14-day dogma.
Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study.
Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease
Questioning the 14-day dogma in candidemia treatment duration.
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey.
COVID-19 associated Pulmonary Aspergillosis in Patients Admitted to the Intensive Care Unit: Impact of Antifungal Prophylaxis.
Performance of the clarus Aspergillus galactomannan enzyme immunoassay prototype for the diagnosis of invasive pulmonary aspergillosis in serum.
Antifungal prophylaxis of COVID-19 associated pulmonary aspergillosis in ventilated patients: one solution does not fit all.
European Study of Cerebral Aspergillosis treated with Isavuconazole (ESCAI): A study by the ESCMID Fungal Infection Study Group.
Soluble Urokinase Plasminogen Activator Receptor (SuPAR) Analysis for Diagnosis of Periprosthetic Joint Infection
Soluble Urokinase Plasminogen Activator Receptor (SuPAR) Analysis for Diagnosis of Periprosthetic Joint Infection.
Correction: Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey.
Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study (Preprint)
Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study
Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study
Social determinants of health as drivers of fungal disease
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA).
Predictors for Prolonged Hospital Stay Solely to Complete Intravenous Antifungal Treatment in Patients with Candidemia: Results from the ECMM Candida III Multinational European Observational Cohort Study.
Predictors for Prolonged Hospital Stay Solely to Complete Intravenous Antifungal Treatment in Patients with Candidemia: Results from the ECMM Candida III Multinational European Observational Cohort Study
Point-of-care testing for viral-associated pulmonary aspergillosis
The Austrian landscape of diagnostic capacity and access to treatment for invasive fungal infections.
Fungal translocation measured by serum 1,3-ß-D-glucan correlates with severity and outcome of liver cirrhosis-A pilot study.
Which trial do we need? Combination treatment of Pneumocystis jirovecii pneumonia in non-HIV infected patients.
COVID-19-Associated Pulmonary Aspergillosis Isolates Are Genomically Diverse but Similar to Each Other in Their Responses to Infection-Relevant Stresses.